Business
Pre-clinical Data
Pre-clinical Data.
About this update from Immupharma Plc
[{"type":"text","content":"\n RNS Number : 8204U Immupharma PLC 20 May 2008 \n \n\n\n\n\nFor Immediate Release\n\n\n20 May 2008\n\n\n\n\n\n \nImmuPharma PLC\n\nImmuPharma's cancer drug candidate IPP- 204106 shows complete response to tumours in multiple human cancer cell lines\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106.\n\nData on ImmuPharma's anti-cancer nucleolin antagonist ('Nucant') peptide programme, IPP-204106 have been obtained confirming the ability of the compounds to effectively control and stop the growth of a large panel of human cancer cell lines both 'in vitro' and 'in vivo'. Collectively the studies comprised breast cancer, prostate cancer, melanoma, glioblastoma, leukaemia, colon cancer and pancreatic cancer cell lines. \n\nThe schedule of administration was typically 10 injections over 2 weeks at doses in the range of 1 mg/kg body weight. 'In vivo' studies showed that the majority of tumours were completely eradicated and survival time increased without additional treatment.\n\nImmuPharma has filed appropriate patents on the composition of matter relating to the peptides covering a large variety of Nucant structures. Manufacturing processes transferable to large scale production have also been successfully developed.\n\nDue to the considerable progress made, ImmuPharma has initiated the regulatory studies necessary for the development program of IPP-204106, and ImmuPharma is pursuing grant opportunities from the French national research agencies.\n\nIn addition to cancer indications, ImmuPharma believes that Nucants could have use in other areas such as psoriasis, wound healing and diabetic retinopathy and these are currently under investigation in research programs conducted by the CNRS teams and ImmuPharma.\n\nRichard Warr, ImmuPharma's Chairman, commented: \n'We are delighted by the pre-clinical data shown in our proprietary candidate for oncology. Furthermore, this exciting new drug candidate has a tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic. This has enhanced further...